Stock comparison
Amneal Pharmaceuticals
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMRX
Amneal Pharmaceuticals
Market cap
$3.96B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMRX | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 69B | MTD |
| Benjamin Graham | 57D | 65B | MTD |
| Philip Fisher | 63C | 63C | Tie |
| Peter Lynch | 54C | 66B | MTD |
| Joel Greenblatt | 31F | 68B | MTD |
| Charlie Munger | 53D | 74B | MTD |
| Terry Smith | 42D | 70B | MTD |
Side-by-side metrics
| Metric | AMRX | MTD |
|---|---|---|
| Market cap | $3.96B | $22.29B |
| P/E (TTM) | 32.1x | 25.3x |
| EV/EBIT | 14.9x | 21.6x |
| ROIC (TTM) | 12.64% | 36.09% |
| Gross margin | 38.66% | 57.79% |
| Net margin | 4.02% | 21.4% |
| Revenue CAGR 5y | 9.58% | 2.01% |
| EPS CAGR 5y | 34.63% | 6.12% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMRX leads on
- EPS CAGR 5y34.63%vs 6.12%+82%
- Revenue CAGR 5y9.58%vs 2.01%+79%
- EV/EBIT14.9xvs 21.6x+31%
- Debt / Equity-vs -+10%
MTD leads on
- Market cap$22.29Bvs $3.96B+82%
- Net margin21.4%vs 4.02%+81%
- ROIC (TTM)36.09%vs 12.64%+65%
- Gross margin57.79%vs 38.66%+33%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.